Leadership Growth Recent leadership appointments paired with a major equity financing led by OrbiMed signal stronger governance and growth momentum, enabling investment in sales infrastructure and clinical education to scale adoption of PM CDT devices.

Clinical Focus Thrombolex targets pulmonary embolism and other thromboembolic diseases with pharmaco mechanical lysis based on the BASHIR endovascular catheter platform, and with a portfolio of FDA cleared devices the company can partner with interventional radiology and vascular labs to drive adoption and demonstrate improved outcomes.

Strategic Funding The Series A backing from OrbiMed with support from current investors provides capital and credibility to expand market reach, fund clinical studies and establish partnerships with hospital networks and distributors to accelerate sales.

Distinctive Advantage Thrombolex offers a differentiated pharmaco mechanical lysis solution with multiple FDA cleared devices based on the BASHIR platform, presenting an opportunity to position as a specialist partner that complements larger device ecosystems through training, service, and fast on site support.

Go To Market As a small, agile team the company can pursue selective partnerships with mid size to large distributors and hospital networks, leveraging clinical education and case studies to accelerate adoption of PM CDT therapies.